A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)

NCT05721950 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

154

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Brigatinib

Sponsor

Takeda